

NORTH CAROLINA GENERAL ASSEMBLY AMENDMENT House Bill 259

AMENDMENT NO.	A1
(to be filled in by	
Principal Clerk)	
	D 1

H259-AMR-13 [v.5]

Page 1 of 2

Amends Title [NO] Second Edition Date _____,2023

Representative K. Baker

1 2 3 4 5 6 7 8 9	moves to amend the bill on page 204, line 9, by rewriting that line to read: "" § 108A-54.2. Procedures for changing medical-<u>clinical coverage</u> policy."; and
10	to amend the bill on page 204, lines 13-26, by rewriting the lines to read:
11	"(e) The Department shall provide coverage of a new prescription medication approved
12	by the Food and Drug Administration (FDA) that becomes available to the public if (i) the
13	manufacturer of that medication is enrolled in the Medicaid Drug Rebate Program and (ii) the
14	medication is approved for the treatment of any of the following conditions, as defined by the
15	most recent edition of the Diagnostic and Statistical Manual of Mental Disorders:
16	(1) <u>Bipolar disorders, hypomanic, manic, depressive, and mixed.</u>
17	(2) Childhood and adolescent depression.
18	(3) Major depressive disorders, single episode or recurrent.
19	(4) Obsessive-compulsive disorders.
20	(5) Paranoid personality disorder and other psychotic disorders.
21	(6) <u>Schizo-affective disorders, bipolar or depressive.</u>
22	(7) <u>Schizophrenia.</u>
23	If the new prescription medication approved for the treatment of any of the preceding
24	conditions is not manufactured by a manufacturer enrolled in the Medicaid Drug Rebate Program,
25	then, no later than the end of the next calendar quarter following the date the new prescription
26	medication became available to the public, the Department shall, in consultation with the
27	Physician's Advisory Group, review and submit a proposed policy to the Preferred Drug List (PDL) Paview Paral recording the inclusion of the new preservition mediation as either a
28 29	(PDL) Review Panel regarding the inclusion of the new prescription medication as either a preferred or non-preferred drug on the Department's PDL.""; and
29 30	preferred of non-preferred drug on the Department's FDL. , and
31	
32	





H259-AMR-13 [v.5]

Page 2 of 2

- 1 to amend the bill on page 204, line 32, by inserting the following at the end of the line:
- 2 "The PDL Policy Review Panel shall meet no less than once a quarter.".

3

SIGNED _____

Amendment Sponsor

SIGNED

Committee Chair if Senate Committee Amendment

ADOPTED _____ FAILED _____ TA

TABLED _____

The official copy of this document, with signatures and vote information, is available in the House Principal Clerk's Office